← Back to screener

Aquestive Therapeutics, Inc. AQST

Rank #1957 · Nasdaq · $0.5B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
37.9
P/E
-11.1
P/B
-4.58
ROE
41.4%
Op. Margin
-53.5%
Debt Ratio
-152%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -11.1x, P/B -4.58x. Ranks in the top 92% of the universe.

Profitability ★★★☆☆
Average

ROE 41.4%. Ranks in the top 48% of the universe.

Safety ★★★★★
Excellent

Debt ratio -152%. Ranks in the top 6% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★☆
Good

Revenue growth of 13.8% year over year. Ranks in the top 27% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2018$0.1B$-0.0B$-0.0B$-0.1B-0.2-122
2019$0.1B$-0.0B$-0.1B$-0.0B-72.6-290
2020$0.1B$-0.1B$-0.1B$0.0B-100.1839
2021$0.0B$-0.0B$-0.1B$-0.0B-93.6-1819
2022$0.1B$-0.0B$-0.1B$-0.0B-68.2-297
2023$0.0B$-0.0B$-0.1B$-0.1B-88.2-214
2024$0.1B$-0.0B$-0.0B$-0.1B-29.9-138
2025$0.1B$-0.0B$-0.0B$-0.1B-53.5-152

← See the full screener